Pasithea Therapeutics Stock (NASDAQ:KTTA)

Revenue Ownership Financials Chart

Previous Close

$3.93

52W Range

$3.61 - $17.40

50D Avg

$4.97

200D Avg

$6.38

Market Cap

$4.04M

Avg Vol (3M)

$13.33K

Beta

0.74

Div Yield

-

KTTA Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Sep 15, 2021

Website

KTTA Performance

KTTA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$486.56K	$15.06K
Operating Income	$-15.98B	$-14.82M	$-4.51M
Net Income	$-15.96B	$-13.06M	$-2.17M
EBITDA	$-15.98B	$-14.74M	$-4.51M
Basic EPS	$-13.01	$-0.52	$-0.21
Diluted EPS	$-13.01	$-0.52	$-0.21

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
BWV	Onconetix, Inc.
ABVC	ABVC BioPharma, Inc.
KPRX	Kiora Pharmaceuticals, Inc.
PXMD	PaxMedica, Inc. Common Stock
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
HILS	Tharimmune, Inc.
KRON	Kronos Bio, Inc.
VRAX	Virax Biolabs Group Limited
MNOV	MediciNova, Inc.
RNXT	RenovoRx, Inc.
INDP	Indaptus Therapeutics, Inc.
KZR	Kezar Life Sciences, Inc.
FBRX	Forte Biosciences, Inc.
ELYM	Eliem Therapeutics, Inc.